Low-dose azithromycin combine with tiotropium powder inhalants therapy of stable chronic obstructive pulmonary disease clinical feasibility analysis and impact of inflammatory cytokine

Abstract

Listen

Translate article

Objective To research low-dose azithromycin combine with tiotropium powder inhalants therapy of stable COPD clinical feasibility analysis and impact of inflammatory cytokine. Methods 100 patients from March 2014 to March 2016 in our hospital with stable COPD and 50 volunteers (NS group) were selected.100 patients were randomly divided into tiotropium group (A group) and combined treatment group (B group), A group were given tiotropium bromide inhalation powder therapy and B group received azithromycin oral plus tiotropium inhalation powder therapyon in the basis of routine treatment.Observe the frequency of acute exacerbation of hospitalization, pulmonary function, an C-reactive protein indicators after one year, A group and B group patients were enzyme linked immunosorbent assay(ELISA) to detect the expression of patient′s blood cytokine PTX3, TNF-α, IFN-γ, IL-2, IL-6 after the treatment of 12, 24, 48 h, which were compared with NS group. Results Adverse reactions in each group of patients with mild, which had no significant difference (P>0.05); Compared with A group, B group aseizure frequency, lung function and inflammatory indicators showed statistically significant difference (P 0.05) in 12, 24, 48 h. B group of TNF-α, PTX3 was sustain lower and was statistically significant difference (P 0.05). Conclusions Low-dose of azithromycin combine with tiotropium powder inhalation therapy can improve lung function in patients with stable COPD and endurance activities to improve the quality of life and reduce the frequency of acute attacks, the expression of the blood PTX3, TNF-α is relatively more lower. Key words: Chronic obstructive pulmonary disease; Azithromycin; PTX3; Enzyme linked immunosorbent assay; Tiotropium; Inflammatory cytokine